o2h discovery

Accelerating Early-Stage Drug Discovery

The o2h Kickstarter Award

ft. The Platinum Partner Programme

A competitive award providing early-stage biotech companies with integrated drug discovery expertise to reach their next milestone.



About

The Kickstarter Award

Track Record

8+	50	$9M+
Editions across the globe	Awards provided so far	Invested in resources

The o2h Kickstarter Awards were first launched in 2022, to provide new therapeutic-focused startups with a 'boost' of chemistry to help achieve initial milestones to enable them to generate the data required to unlock further funding.

To date, we have provided more than 50 Kickstarter awards in the UK, the USA, Australia, Israel and Europe. Many of these companies have continued their growth off the back of this award since joining the program in 2022, and we are proud to have supported them through their early launch.

Benefits

Team

A dedicated team of six FTE synthetic chemists of which two are senior and four are junior chemists

Cost & Duration

Six synthetic chemists at a fraction of the usual price for up to six months

Additional Support

Receive 100 complimentary ADME points and save 20% on Biology FTE

Inventory

Access to a large inventory of chemicals and reagents for synthesis

Scan to know more about **The o2h Kickstarter competition**

Scan to know more about **o2h Kickstarter: North America**

Latest Edition

The o2h Kickstarter: Peptide

Exclusively for Peptide-focused biotech startups

About o2h Kickstarter: Peptide

From Small Molecules to Peptides

The o2h Kickstarter was originally launched to support early-stage biotech companies in accelerating small-molecule drug discovery. Building on strong demand from the biotech community, the programme now extends to peptide therapeutics, with a dedicated edition designed for startups working on peptide-based drug discovery.

This expansion reflects the increasing role of peptides in modern drug discovery and o2h's continued focus on supporting innovation across modalities. The programme is structured to enable progression from early hit identification through to IND-enabling stages, with integrated scientific support to move programmes forward.

How it works?

The Peptide Kickstarter is structured in two stages, giving startups both an initial discovery push and a clear pathway to continued support.

Stage I - Discovery

A defined piece of work to generate early, decision-relevant data

In Stage I, Selected companies will receive:

- 100 peptides synthesis (linear & cyclic)
  (at a fraction of the usual price)
- 25 ADME data points
- 20% discount on Biology FTEs
- End-to-end project management

Stagle II - Continued Development

Dedicated support to advance your peptide pipeline

Following a successful Stage I, participating companies can continue into Stage II and get:

- Dedicated FTE engagement
  (at a fraction of the usual price for upto 6 months)
- 75 additional ADME data points
- 20% discount on Biology FTEs
- Focus on optimisation and further profiling

Programme Benefits *(What you get)*

- **Peptide Synthesis, Delivered with Precision**
- **End-to-End Chemistry, Built for Execution**
- **ADME Built Into the Programme**
- **Biology Support, on Demand**

Scan to know more about ***The o2h Kickstarter: Peptide***

o2h Kickstarter Winners' Wall

Over the years, we have become a trusted discovery partner to early-stage life science, biotech, and techbio companies, helping them translate innovative ideas into meaningful scientific progress and successful funding outcomes.

Cellestial Health
Awen Oncology
Azadyne
OROGEN
SCITHERA
Keystone
5 ALARMBIO
Breakloop
scripta therapeutics
cosMYC
KUANO
SERINUS
InnoVira
Ternary Tx
ZPrime
GRADIENT
Permanence Bio
PROTEKT Therapeutics
Synprox
Jefferson Thomas Jefferson University
University of Glasgow
Neurovation LABS
Atelier Tx Powering Vitality
SiftrBio
Type6 THERAPEUTICS
PANNEX THERAPEUTICS
Protai
HADO THERAPEUTICS
Galilei Biosciences
MONASH University
PSYLO
alevin THERAPEUTICS
ST4TE therapeutics
ORIGAMI Therapeutics
TAY THERAPEUTICS
TRBO TR Beta Oncology
UCSF University of California San Francisco
Iterion THERAPEUTICS
ADULARIA
HOX THERAPEUTICS
MOLECULAR GLUE LABS
TRIMTECH THERAPEUTICS
PSY THERAPEUTICS
PAM therapeutics
VEIRULENCE
SEVENLESS
Photo 51
KLYV Therapeutics
serenatis bio

Meet the Kickstarter Winners

Since its launch, the o2h Kickstarter Award has supported innovative biotech companies and academic spinouts from around the world, helping them generate critical scientific data and reach their next milestone.

Winning the o2h Kickstarter Award is a tremendous validation of our team's dedication to solving the MYC problem in cancer. The expertise and collaborative support provided by the o2h team are actively accelerating our hit-to-lead chemistry efforts. This partnership is instrumental in helping us rapidly advance our first-in-class MYC:TRRAP inhibitors from the laboratory toward the clinic, bringing us one step closer to addressing a critical unmet need in oncology.



Dr. Ed Feris
CEO, ***cosMYC***



We are deeply grateful to the o2h Kickstarter program for their invaluable support in advancing our small molecule discovery efforts. This partnership has enabled us to expand our compound portfolio and accelerate the lead optimization phase of our lead program. Support from initiatives like o2h Kickstarter plays a crucial role in helping early-stage biotech companies translate scientific innovation into tangible therapeutic opportunities

Ana Montalban
CEO & Co-founder, ***Adularia***

The Kickstarter has been pivotal for our development progress. Medchem can be expensive and challenging for early-stage biotechs, but we are now enjoying the momentum this high-quality chemistry programme brings to our lead optimisation. We had heard good things about the Kickstarter before we applied and I am happy to pass on that positivity from our own experience.



Rory Triniman
CEO & Founder, ***Veirulence Ltd***

o2h Discovery Platinum Partner

An exclusive benefit that helps you deliver more value to your portfolio

About

Extending the o2h Kickstarter Award to More Biotech Innovators

Through the o2h Kickstarter Award, we've supported 50 early-stage biotech companies across the UK, USA, Europe, Australia and Israel. Building on its success, we created the Platinum Partner Programme to help even more innovators access specialist drug discovery support during their earliest stages of growth.

The programme enables venture capital firms, venture builders, universities, incubators and technology transfer offices to extend the benefits of the o2h Kickstarter Award directly to eligible companies within their portfolio or ecosystem.

By combining investment and ecosystem support with o2h Discovery's integrated drug discovery expertise, Platinum Partners help founders generate critical scientific data, reduce development risk and accelerate progress towards key technical and fundraising milestones.

Benefits for Portfolio Companies

- A dedicated team of six synthetic chemists for up to six months to accelerate small molecule discovery programmes
- High-purity linear, cyclic and constrained peptide synthesis supports to rapidly expand peptide SAR programmes
- 100 complimentary ADME points and a 20% discount on biology services
- Integrated project management support delivered through o2h Discovery's multi-disciplinary discovery teams

Benefits for Platinum Partners

- **Add Value Beyond Capital**
- **Strengthen Portfolio Success**
- **Differentiate Your Ecosystem**
- **A Trusted Discovery Partner**

Our Platinum Partners

Stevenage Bioscience Catalyst · Milner Therapeutics Institute · o2h ventures · zinc · Persephoni (Discover | Transform | Accelerate) · Essential NeuroVentures · Cancer Research UK · Pioneer · mercia Ventures · Linchpin.Bio Consulting Network · Yale Ventures · Monash University · Monash Institute of Pharmaceutical Sciences

The o2h Kickstarter Award was created to help early-stage biotech companies access the scientific expertise and discovery capabilities needed to reach their next milestone. Over the past few years, we've had the privilege of supporting more than 50 startups globally, and the Platinum Partner Programme is a natural extension of that journey. We are delighted to welcome all the Platinum Partners and look forward to working together to help more founders accelerate their science and build successful biotechnology companies.



Sunil Shah
Co-founder, ***o2h Discovery***



Our role is to back exceptional founders and help them overcome the challenges of building breakthrough companies. For many biotech businesses, that means providing access not only to capital but also to the specialist scientific expertise needed to generate robust data and validate their science. By joining the o2h Discovery Platinum Partner Programme, we're strengthening the support available to our life sciences portfolio and giving founders access to another valuable resource as they move from promising science towards commercial success.

Amrit Singh Sami
Investor, ***Mercia Ventures***

We're delighted to become a Platinum Partner of the o2h Kickstarter Programme. Supporting early-stage life science companies is at the heart of what we do at the Milner Institute's Bio-incubator, and this partnership will help more founders access the expertise and resources they need to accelerate their science.

We've already seen the value of the programme through our former resident company, TRIMTECH Therapeutics, which received an o2h Kickstarter Award and worked with the o2h Discovery team to advance its medicinal chemistry programme and targeted protein degradation platform. We look forward to building on that success and helping the next generation of biotech companies translate promising science into new therapies.



Alexandra Huener
Head of Entrepreneurship,
Milner Therapeutics Institute

o2h Kickstarter Evolution Across Key Milestones

Therapeutics

Discovery | Pre-clinical | Phase I | Phase II | Phase III | Marketed



Area: CNS / Neuroscience **Focus:** Psychedelics for CNS



Area: Oncology **Focus:** Hepatocellular Carcinoma, Paediatric Osteosarcoma



Area: Neurodegenerative **Focus:** Alzheimer's / Huntington



Area: CNS / Neuroscience **Focus:** OCD Therapeutics



Area: Neurodegenerative **Focus:** Alzheimer's & Parkinson's



Area: Oncology **Focus:** Antibody-Drug Conjugates



Area: Immunology / Autoimmune **Focus:** Queuine mimetics (QTRT pathway) for MS



Area: Oncology **Focus:** Prostate Cancer



Area: TPD **Focus:** Protein degradation (Inflammation & Fibrosis)




Area: Oncology **Focus:** Prostate Cancer



Area: Metabolic Disorders **Focus:** Obesity



Area: Oncology and Neurology **Focus:** Cancer and Neurological Disease



Area: Oncology **Focus:** Precision Oncology



Area: Oncology **Focus:** TRβ Activation, Aggressive & Metastatic Solid Tumors



Area: CNS / Neuropsychiatry **Focus:** Small-Molecule precision Neuromodulators, Lead focus on PTSD



Area: CNS / Neuropsychiatry **Focus:** Cognitive Impairment, Schizophrenia



Area: Oncology **Focus:** Protection against DNA damage and Radiation-Induced Tissue Injury



Area: Oncology (Solid Tumours) **Focus:** GI, Prostate, Gynaecological Cancers



Area: Immunology & Inflammation **Focus:** Dermatology, Rheumatology, Gastroenterology



Area: CNS / Neuroscience **Focus:** PTSD & Depression



Area: Metabolic Disorders / Inflammation **Focus:** Metabolic Health & Chronic Inflammation



Area: Oncology **Focus:** AML, Melanoma, CRC

	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Marketed
Galilei Biosciences	**Area:** Ageing & Regenerative / Oncology **Focus:** Anti-Ageing Molecules / Cancer					
VEIRULENCE	**Area:** Anti-Infectives **Focus:** Flagella Inhibitors					
Type6 Therapeutics	**Area:** Oncology **Focus:** Kinase Inhibitors					
InnoVira	**Area:** Infectious Diseases / Autoimmune **Focus:** EBV & Autoimmune Inhibitors					
ORIGAMI Therapeutics	**Area:** Neurodegenerative **Focus:** Huntington's TPD					
PROTEKT Therapeutics	**Area:** Neurodegenerative **Focus:** Neurodegenerative & Inflammatory					
GERTRUDE BIOMEDICAL	**Area:** Oncology **Focus:** Cancer Transcription Inhibitors					
SEVENLESS	**Area:** Multi-Therapeutics **Focus:** Cancer, Pain, Dementia					
ADULARIA	**Area:** Oncology **Focus:** Immunotherapy					
HADO THERAPEUTICS	**Area:** Immuno-Oncology **Focus:** Glioblastoma, Parkinson's Disease, Diabetic Neuropathy and Bleeding Disorders					
SiftrBio	**Area:** Oncology **Focus:** Antibody-Drug Conjugates					
Photo 51	**Area:** Oncology **Focus:** Multiple Cancers					
GRADIENT	**Area:** Pain **Focus:** Small-Molecule Therapeutics for Chronic and Acute Pain					
Awen Oncology	**Area:** Oncology **Focus:** Oncology Drug Discovery					
Breakloop	**Area:** Neurodegeneration **Focus:** Neuroimmune Injury					
Synprox	**Area:** Drug Discovery **Focus:** Oncology Drug Discovery					
KLYV Therapeutics	**Area:** Cardiology **Focus:** Anti-Fibrotic Therapies for Heart Failure					

Platform Biotech

	Proof of Concept	Platform Validation	Pipeline Expansion	Strategic Partnerships	Clinical Advancement	Commercial Readiness	Market Leadership
MOLECULAR GLUE LABS	**Area:** Oncology **Focus:** Molecular Glues (PPIs)						

Tech Bio

	Proof of Concept	Algorithm/ Platform Validation	Pipeline Expansion	Strategic Partnerships	Clinical Advancement	Commercial Readiness	Market Leadership
Protai	**Area:** Drug Discovery (Oncology and Immunology / Inflammation) **Focus:** Protein-level Disease Mapping						
SERINUS	**Area:** Oncology **Focus:** Rational Combination Therapy, Drug Resistance, Precision Medicine						
scripta therapeutics	**Area:** CNS / Neuroscience **Focus:** Alzheimer's, Parkinson's and ALS.						







OBN Awards 2025 & 2023

o2h Discovery won the “Best Industry Support Partner of the Year” and “Most Impactful CRO of the Year” awards at the industry-leading OBN Awards at the 2025 & 2023 respectively.



OBN Special Recognition Award for contribution to the life science industry

o2h discovery

Seeding New Ideas...

o2h Discovery has a multi-modality integrated drug discovery platform, operating from its state-of-the-art research centres in Cambridge, UK, and Ahmedabad, India. We execute hit-lead-optimisation programmes leading into patent and IND filing with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development.

UK
Mill scitech park
Mill lane
Hauxton
Cambridge
CB22 5HX

USA
CIC Cambridge
1 Broadway
Cambridge
MA 02142

India
Sharmista Research Centre
35, Panchratna Ind. Estate
Changodar, Sarkhej Bavla Road
Ahmedabad
Gujarat 382213

Scan and Discover More



For more information or to get a quote contact us at: **discovery@o2h.com**

o2h-discovery o2hgroup o2hlife o2hlife o2h_discovery